Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and
development-focused biotechnology company dedicated to creating small
molecule drugs for viral infections and liver diseases, today announced
that Jay R. Luly, Ph.D., President and Chief Executive Officer, will
participate in a fireside chat format, or question and answer session,
with investors on May 7, 2015 at 2:10 p.m. ET during the Deutsche Bank 40th
Annual Healthcare Conference in Boston.
A live webcast and replay of the session can be accessed by visiting the
“Calendar of Events” section on the “Investors” page of Enanta’s website
at www.enanta.com.
The replay webcast will be available following the presentation and will
be archived for approximately 30 days.
About Enanta
Enanta Pharmaceuticals is a research and development-focused
biotechnology company that uses its robust chemistry-driven approach and
drug discovery capabilities to create small molecule drugs for viral
infections and liver diseases. Enanta is discovering, and in some cases
developing, novel inhibitors designed for use against the hepatitis C
virus (HCV). These inhibitors include members of the direct acting
antiviral (DAA) inhibitor classes – protease (partnered with AbbVie),
NS5A, and nucleotide polymerase – as well as a host-targeted antiviral
(HTA) inhibitor class targeted against cyclophilin. Enanta’s lead
protease inhibitor, paritaprevir, is part of AbbVie’s recently approved
HCV treatment regimens. In addition, Enanta has a preclinical program in
non-alcoholic steatohepatitis, or NASH, which is a condition that
results in liver inflammation and damage caused by a buildup of fat in
the liver.
![](http://cts.businesswire.com/ct/CT?id=bwnews&sty=20150427006056r1&sid=ntxv4&distro=nx&lang=en)
Copyright Business Wire 2015